Akari Therapeutics Plc ADR(AKTX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 4:00 PM ET (Korea 10/31 05:00)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -17.25 | Insider Own | 0.4% | Shs Outstand | 1.8M | Perf Week | 0.18% |
| Market Cap | 0.01B | Forward P/E | - | EPS next Y | 44.32% | Insider Trans | - | Shs Float | 1.7M | Perf Month | -6.79% |
| Enterprise Value | 0.01B | PEG | - | EPS next Q | -2.23 | Inst Own | 8.71% | Short Float | 1.01% | Perf Quarter | 11.96% |
| Income | -0.03B | P/S | - | EPS this Y | 52.32% | Inst Trans | 270.4% | Short Ratio | 0.28 | Perf Half Y | 50.64% |
| Sales | 0.00B | P/B | 0.78 | EPS next 5Y | 46.65% | ROA | -69.02% | Short Interest | 0.02M | Perf YTD | -28.72% |
| Book/sh | 10.62 | P/C | 1.86 | EPS past 3/5Y | - | ROE | -139.8% | 52W High | -75.48% ($33.60) | Perf Year | -71.79% |
| Cash/sh | 4.43 | P/FCF | - | Sales past 3/5Y | - | ROIC | -166.16% | 52W Low | 173.3% ($3.02) | Perf 3Y | -94.43% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | - | Gross Margin | - | Volatility(W/M) | 13.21% 12.09% | Perf 5Y | -99.38% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 1.09 | Perf 10Y | -99.88% |
| Dividend Ex-Date | - | Quick Ratio | 0.6 | EPS Q/Q | 1.39% | Profit Margin | - | RSI (14) | 46.96 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.6 | Sales Q/Q | - | SMA20 | -2.78% ($8.48) | Beta | 1.46 | Target Price | $25.5 |
| Payout | - | Debt/Eq | 0.04 | Earnings | 2026/8/13 | SMA50 | -11.25% ($9.28) | Rel Volume | 0.73 | Prev Close | $8 |
| Employees | 6 | LT Debt/Eq | 0 | EPS/Sales Surpr. | 100% - | SMA200 | -9.05% ($9.06) | Avg Volume(3M) | 0.06M | Price | $8.24 |
| IPO | 2013/5/7 | Option/Short | Yes/Yes | Trades | 742 | Volume | 45,801 | Change | 3% |
A clinical-stage oncology biotech developing next-generation antibody-drug conjugates (ADCs). Its lead candidate, AKTX-101, is a Trop2-targeted ADC built on a proprietary PH1 spliceosome-inhibiting payload and features a mechanism of action that differentiates it from existing ADCs.
Over the past 1 year, on the lower side
75% below its 1-year high.
Traded less than usual. That is 73% of its average volume.
AKTX has weak earnings and a weak balance sheet
Review management risk carefully before investing
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +52.3% this year.
Tap to view numbers
Not enough quarters to judge yet
Only 2 quarter(s) reported, so no grade yet.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -99.4%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 8.7%.
Tap to view numbers
It ranks #480 of 597 in the industry
Based on market cap of $14M.
KPTI#479 Karyopharm Therapeutics Inc $15M PER - AKTX#480 Akari Therapeutics Plc ADR $14M PER - 
CTXR#481 Citius Pharmaceuticals Inc $14M PER - 
ALLR#482 Allarity Therapeutics Inc $14M PER - 
DARE#483 Dare Bioscience Inc $14M PER - 
FAQ
What kind of company is AKTX?
AKTX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of AKTX?
The market cap of AKTX is approximately $14M, ranking 5,314 within its sector.
What is the 52-week high and low for AKTX?
AKTX has recorded a 52-week high of $33.60 and a low of $3.02.
